Why the study?
Do urinary CD59 glycoprotein and alpha-1 antitrypsin predict the development of albuminuria in hypertensive patients under chronic RAS suppression?
Do urinary CD59 glycoprotein and alpha-1 antitrypsin predict the development of albuminuria in hypertensive patients under chronic RAS suppression?
Urinary CD59 and alpha-1 antitrypsin may serve as early predictors of albuminuria development in hypertensive patients on chronic RAS suppression, potentially identifying those at higher cardiovascular risk before classical markers become abnormal.
No takes yet. Share an insight, caveat, or question.
Urinary CD59 and AAT may flag progression risk in treated hypertensives; leaves open whether they improve stratification or guide therapy.
Gonzalez‐Calero et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: